Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.15 -7.3%	$2.59	$1.78 ▼ $10.14	$48.47M	0.71	268,907 shs	254,487 shs
BLUE bluebird bio	$4.97	$4.63	$3.20 ▼ $28.60	$48.67M	0.27	440,182 shs	N/A
CLLS Cellectis	$1.53 +5.2%	$1.48	$1.10 ▼ $2.43	$80.60M	2.93	142,732 shs	55,219 shs
EDIT Editas Medicine	$2.20 -3.5%	$1.78	$0.91 ▼ $6.05	$190.87M	2.1	2.57 million shs	2.24 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	-7.33%	-3.59%	-2.71%	-43.86%	-68.66%
BLUE bluebird bio	0.00%	0.00%	0.00%	-5.33%	-74.75%
CLLS Cellectis	+5.17%	+5.90%	+5.39%	+15.53%	-18.45%
EDIT Editas Medicine	-3.51%	+4.76%	+26.80%	+94.69%	-52.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	4.2947 of 5 stars	3.4	3.0	4.8	1.7	2.5	0.6
BLUE bluebird bio	2.1331 of 5 stars	3.1	0.0	0.0	1.6	1.7	1.3
CLLS Cellectis	2.9787 of 5 stars	3.5	3.0	0.0	2.5	2.5	0.6
EDIT Editas Medicine	4.2283 of 5 stars	3.2	3.0	4.2	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$23.80	1,006.98% Upside
BLUE bluebird bio	2.25	Hold	$44.60	797.38% Upside
CLLS Cellectis	3.00	Buy	$4.00	162.30% Upside
EDIT Editas Medicine	2.31	Hold	$4.70	113.64% Upside

Current Analyst Ratings Breakdown

Latest EDIT, ADVM, CLLS, and BLUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $12.00
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/13/2025	CLLS Cellectis	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$5.00 ➝ $4.00
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00
4/29/2025	EDIT Editas Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
4/17/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $33.00
4/16/2025	ADVM Adverum Biotechnologies	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$10.00 ➝ $5.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	44.91	N/A	N/A	$3.40 per share	0.63
BLUE bluebird bio	$103.95M	0.47	N/A	N/A	$35.59 per share	0.14
CLLS Cellectis	$49.22M	1.72	N/A	N/A	$2.36 per share	0.65
EDIT Editas Medicine	$32.31M	5.70	N/A	N/A	$1.63 per share	1.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$6.40	N/A	N/A	N/A	N/A	-130.53%	-66.31%	8/11/2025 (Estimated)
BLUE bluebird bio	-$211.91M	-$41.32	N/A	N/A	N/A	-565.74%	-322.46%	-53.17%	8/12/2025 (Estimated)
CLLS Cellectis	-$36.76M	-$0.86	N/A	N/A	N/A	-114.82%	-62.55%	-21.19%	8/5/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-701.06%	-139.24%	-63.87%	8/6/2025 (Estimated)

Latest EDIT, ADVM, CLLS, and BLUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	CLLS Cellectis	-$0.1540	-$0.18	-$0.0260	-$0.18	$12.71 million	$12.03 million
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million
4/15/2025	Q4 2024	ADVM Adverum Biotechnologies	-$1.34	-$1.96	-$0.62	-$1.96	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
BLUE bluebird bio	N/A	N/A	N/A	N/A	N/A
CLLS Cellectis	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	3.57	3.57
BLUE bluebird bio	0.37	0.51	0.33
CLLS Cellectis	0.44	1.67	1.67
EDIT Editas Medicine	N/A	3.08	3.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
BLUE bluebird bio	87.43%
CLLS Cellectis	63.90%
EDIT Editas Medicine	71.90%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
BLUE bluebird bio	1.40%
CLLS Cellectis	16.41%
EDIT Editas Medicine	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.64 million	Optionable
BLUE bluebird bio	520	9.79 million	9.59 million	Optionable
CLLS Cellectis	290	55.58 million	46.46 million	Optionable
EDIT Editas Medicine	230	83.71 million	82.12 million	Optionable

EDIT, ADVM, CLLS, and BLUE Headlines

Recent News About These Companies

Wall Street Zen Upgrades Editas Medicine (NASDAQ:EDIT) to "Hold"

June 29 at 2:35 AM | americanbankingnews.com

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?

June 28 at 5:04 AM | fool.com

Editas Medicine (NASDAQ:EDIT) Upgraded by Wall Street Zen to Hold Rating

June 27, 2025 | marketbeat.com

Editas Medicine Inc. Annual Cash Flow Statement - MarketWatch

June 25, 2025 | marketwatch.com

Editas Medicine Inc.

June 25, 2025 | barrons.com

Gene editors steady despite latest leadership shake-up at FDA

June 20, 2025 | msn.com

Lilly-Verve deal sends gene editing stocks higher

June 17, 2025 | msn.com

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

June 17, 2025 | msn.com

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Hold" from Brokerages

June 17, 2025 | marketbeat.com

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

June 12, 2025 | globenewswire.com

RFK Jr. Just Supercharged These 2 Biotech Penny Stocks

June 11, 2025 | msn.com

Why Is Editas (EDIT) Up 40% Since Last Earnings Report?

June 11, 2025 | zacks.com

Bank of America Corp DE Reduces Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT)

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Comments on Editas Medicine FY2026 Earnings

June 10, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in Editas Medicine, Inc. (NASDAQ:EDIT)

June 9, 2025 | marketbeat.com

Ameriprise Financial Inc. Purchases 168,134 Shares of Editas Medicine, Inc. (NASDAQ:EDIT)

June 6, 2025 | marketbeat.com

Editas Medicine, Inc. (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 15,192 Shares

June 5, 2025 | marketbeat.com

Editas Medicine, Inc. (NASDAQ:EDIT) CEO Sells $26,130.24 in Stock

June 5, 2025 | insidertrades.com

Editas Medicine Q2 EPS Estimate Increased by Zacks Research

June 4, 2025 | marketbeat.com

Editas Medicine Stockholders Approve Key Amendments

June 2, 2025 | tipranks.com

Editas Medicine, Inc. (NASDAQ:EDIT) Short Interest Down 21.7% in May

June 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EDIT, ADVM, CLLS, and BLUE Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.15 -0.17 (-7.33%)

As of 06/30/2025 04:00 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

bluebird bio NASDAQ:BLUE

$4.97 0.00 (0.00%)

As of 06/2/2025

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Cellectis NASDAQ:CLLS

$1.52 +0.08 (+5.17%)

As of 06/30/2025 03:49 PM Eastern

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Editas Medicine NASDAQ:EDIT

$2.20 -0.08 (-3.51%)

As of 06/30/2025 04:00 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time